Gritstone bio reports positive interim Phase 2 data

Gritstone bio, Inc. (NASDAQ:GRTS), a biotechnology company specializing in cancer vaccines, has announced interim results from its Phase 2 study of its personalized cancer vaccine, GRANITE, in patients with advanced colorectal cancer. The study showed promising signs of efficacy and safety, according to a press release statement based on an SEC filing.

The data, cut as of August 19, 2024, included 104 patients with metastatic microsatellite stable colorectal cancer (MSS-CRC) who were randomized to receive either the GRANITE vaccine in combination with immune checkpoint inhibitors or the standard of care. Of these, 69 patients were evaluated, with the majority having liver metastases.

The interim analysis suggested a 21% relative risk reduction of disease progression or death for patients treated with GRANITE compared to the control group. Notably, 33% of GRANITE patients remained free of disease progression.

Furthermore, the vaccine's impact was more pronounced in patients with a low disease burden, as indicated by circulating tumor DNA (ctDNA) levels at study entry. In this subgroup, there was a 38% relative risk reduction of progression or death. Immune responses were also observed, with functional neoantigen-specific T cells detected in all tested GRANITE patients.

The safety profile of GRANITE was favorable, with no treatment discontinuations due to adverse events. The most common side effects were mild, flu-like symptoms typical of potent vaccines.

Gritstone plans to discuss the progression-free survival (PFS) data with the U.S. Food and Drug Administration in the near future to determine the next steps, which may include a Phase 2 or 3 trial using ctDNA levels as a selection criterion for eligibility.

The company's findings are a potential step forward in the treatment of MSS-CRC, a cancer type that often has limited treatment options. The full implications of the study will become clearer as Gritstone bio continues to analyze the data and consult with regulatory authorities.

In other recent news, Gritstone bio has been the subject of significant attention due to recent developments. The company's GRANITE cancer vaccine trial has shown promising interim results, with a potential reduction in disease progression or death in patients with microsatellite stable colorectal cancer. Despite these encouraging results, JMP Securities downgraded Gritstone bio from Market Outperform to Market Perform due to concerns about the company's financial position.

Gritstone's second-quarter report revealed a net loss of $23 million, with cash reserves of $62 million and $40 million in debt. To address financial challenges, Gritstone has engaged Raymond James as a financial advisor to explore strategic options. Meanwhile, other analyst firms such as TD Cowen and Piper Sandler have maintained their positive ratings on the company, highlighting the potential of the GRANITE program.

In addition to these financial and trial updates, Gritstone bio also announced the election of Elaine Jones, Ph.D., and Clare Fisher to its Board of Directors, and the approval of executive officers' compensation by stockholders. These recent developments highlight the ongoing activities within Gritstone bio.

InvestingPro Insights

As Gritstone bio (NASDAQ:GRTS) reports promising interim results for its GRANITE vaccine, investors may benefit from additional financial context. According to InvestingPro data, Gritstone's market capitalization stands at $68.49 million, reflecting the company's current valuation in light of these developments.

InvestingPro Tips highlight that three analysts have revised their earnings upwards for the upcoming period, which could be influenced by the positive Phase 2 study results. However, it's important to note that the company is currently not profitable, with a negative P/E ratio of -0.51 over the last twelve months as of Q2 2024.

Despite the encouraging clinical data, Gritstone faces financial challenges. An InvestingPro Tip indicates that the company is quickly burning through cash, which is a common concern for biotechnology firms in the development stage. This is further reflected in the revenue figures, with Gritstone recording $14.61 million in revenue over the last twelve months as of Q2 2024, and analysts anticipating a sales decline in the current year.

For investors considering Gritstone's potential, it's worth noting that InvestingPro offers 11 additional tips for a more comprehensive analysis of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.